Tesaro
Tesaro[edit]
Tesaro was a biopharmaceutical company focused on developing and commercializing cancer therapeutics. Founded in 2010, Tesaro was headquartered in Waltham, Massachusetts, and became known for its work in oncology, particularly in the development of treatments for ovarian cancer and other solid tumors.
History[edit]
Tesaro was founded by former executives of MGI Pharma, including Lonnie Moulder, Mary Lynne Hedley, and Richard Rodgers. The company quickly gained attention in the biopharmaceutical industry due to its strategic focus on oncology and its ability to secure significant funding for its research and development efforts.
In 2018, Tesaro was acquired by GlaxoSmithKline (GSK) for approximately $5.1 billion, marking a significant expansion of GSK's oncology portfolio.
Products[edit]
Tesaro developed several key products, with a focus on PARP inhibitors and other targeted cancer therapies.
Niraparib (Zejula)[edit]
Niraparib, marketed under the brand name Zejula, is an oral PARP inhibitor used in the treatment of ovarian cancer. It was approved by the U.S. Food and Drug Administration (FDA) in 2017 for use in patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.
Rolapitant (Varubi)[edit]
Rolapitant, marketed as Varubi, is a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It was approved by the FDA in 2015 and is used in combination with other antiemetic agents.
Research and Development[edit]
Tesaro was involved in several clinical trials aimed at expanding the indications for its existing products and developing new therapies. The company's research focused on leveraging its expertise in cancer biology and drug development to create innovative treatments for patients with unmet medical needs.
Acquisition by GlaxoSmithKline[edit]
In December 2018, GlaxoSmithKline announced its acquisition of Tesaro, which was completed in January 2019. This acquisition was part of GSK's strategy to strengthen its oncology pipeline and enhance its capabilities in the development of cancer therapies.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
